HOMEwww.epgonline.orgDRUGSwww.epgonline.orgDISEASE KNOWLEDGEwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgREGISTERwww.epgonline.orgSEARCH
Members
Why a doctor should
Username/Email

Password ()




EPG on Twitter EPG Online Twitter
EPG Online Blog EPG Online Blog
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Search
Languages

ALU-CAP overview
Alu-Cap is recommended for use as a phosphate binding agent in the management of renal failure. It may also be used as an antacid.
banner_pass = 1

Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: English
 
 
Related DrugsDrug Details
ALU-CAP
Drug Class Description :

Antacids.

Generic Name :

Aluminium hydroxide dried gel - hyperacidity

Drug description :

Each capsule contains 475 mg Dried Aluminium Hydroxide Gel Ph Eur as a white powder.

Presentation :

Hard gelatin capsules

Indications :

Alu-Cap is recommended for use as a phosphate binding agent in the management of renal failure. It may also be used as an antacid.

Adult Dosage :

FOR PHOSPHATE BINDING

ADULTS AND CHILDREN: The dosage must be selected in accordance with individual patient requirements, and may range from 4 to 20 capsules of Alu-Cap daily (approximately 2 to 10 g dried aluminium hydroxide gel), taken with meals.

AS AN ANTACID

ADULTS: One Alu-Cap four times daily and on retiring.

CHILDREN: Alu-Cap is not suitable for antacid therapy in children.

ELDERLY: No special dosage recommendations are made for elderly patients.

Child Dosage :

Not recommended. Not recommended.

Contra Indications :

Alu -Cap is contra-indicated in patients with hypophosphataemia and acute porphyria.

Special Precautions :

Phosphate depletion: Aluminium salts may cause phosphate depletion, which is generally negligible. On prolonged treatment with large doses hypophosphataemia may occur, especially in patients with restricted phosphate intake. This syndrome is characterised by anorexia, malaise and muscle weakness. If left unchecked this condition may give rise to osteomalacia. osteoporosis and urinary calculi. Serum phosphate levels should be monitored regularly (bi-monthly) in patients on maintenance haemodialysis who are receiving chronic aluminium hydroxide therapy.

Renal failure: In patients with chronic renal failure. hyperaluminaemia may occur. Aluminium accumulates in the bone, lungs and nerve tissue. Aluminium accumulation in the CNS may be the cause of dialysis dementia which sometimes occurs in chronic renal failure patients receiving long term aluminium therapy for hyperphosphataemia.

Effect on drug absorption: Aluminium hydroxide reduces absorption of tetracyclines and vitamins and may delay the absorption of quinidine (see interactions). Aluminium hydroxide and such drugs should be administered 2 hours apart.

Interactions :

Reported to interfere with absorption of some drugs including tetracyclines. penicillin. sulphonamides, iron, digoxin. indometacin, naproxen. phenylbutazone and vitamins. Aluminium hydroxide and such drugs should be administered 2 hours apart

Adverse Reactions :

Aluminium hydroxide is astringent and may cause constipation.

Manufacturer :

Meda Pharmaceuticals

Drug Availability :

P- pharmacy

Drug Updated :

04 June 2009

Related Drugs - Acid-peptic & motility disorders
Soft Tissue Sarcoma Parkinson's disease (PD) is a degenerative disorder of the central nervous system characterized by the clinically asymmetric onset of resting tremor, bradykinesia, rigidity and postural instability. www.hae-awareness.net is a CPD-accredited interactive training programme for physicians involved in the care and treatment of patients with hereditary angioedema Prostate Cancer
New and updated Drugs
UK Drugs EPG Medical News Feed
Spanish Drugs EPG Medical News Feed
German Drugs EPG Medical News Feed
Norweigan Drugs EPG Medical News Feed
Netherlands Drugs EPG Medical News Feed
Swedish Drugs EPG Medical News Feed
French Drugs EPG French Drugs Feed
Portuguese Drugs EPG Portuguese Drugs Feed
Italian Drugs EPG Italian Drugs Feed

Atopic Dermatitis

Atopic Dermatitis

CONNECT

DISEASE CENTRES Disease Centres feed

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES UK Drug Data Feed

DRUG DATA UK Drug Data Feed

REFERENCES